BT-11 is under clinical development by Landos Biopharma and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BT-11’s likelihood of approval (LoA) and phase transition for Crohn’s Disease (Regional Enteritis) took place on 26 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BT-11 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BT-11 overview

BT-11 is under development for the treatment of inflammatory bowel disease (IBD) like crohn's disease and ulcerative colitis, eosinophilic esophagitis, psoriasis, atopic dermatitis. The drug candidate is administered through oral route. The drug candidate is an arebis (benzimidazoyl) terephthalanilide derivative and targets lanthionine synthetase component C-like protein 2 (LANCL2). It was also under development for the treatment of type 2 diabetes.

Landos Biopharma overview

Landos Biopharma (Landos) is a biopharmaceutical company. It develops oral therapeutics for the treatment of autoimmune diseases. The company pipeline product includes LANCL2, NLRX1, PLXDC2BT-11 small molecule therapeutics for the treatment of anti-inflammatory disease. It utilizes Lanthionine Synthetase C-Like 2 (LANCL2) technology for developing their products. The company is engaged in the development of BT-11 and NX-13 for the treatment of UC and CD. The company serves in the therapeutic areas of inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Landos is headquartered in Blacksburg, Virginia, the US.

Quick View BT-11 LOA Data

Report Segments
  • Innovator
Drug Name
  • BT-11
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Immunology
  • Metabolic Disorders
Key Developers
  • Sponsor Company: Landos Biopharma
  • Originator: Virginia Polytechnic Institute and State University
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.